Fulminant Hepatic Failure due to Nilutamide Hepatotoxicity

  • Shehzad N. Merwat
  • Wareef Kabbani
  • Douglas G. Adler
Case Report


We report the case of a 76-year-old man who developed fulminant hepatic failure after treatment with the anti-androgen nilutamide (Nilandron). Both reversible and fatal liver toxicity have been described in patients treated with flutamide, an analogue of nilutamide, although this has been less commonly described with nilutamide itself [1]. Our patient was prescribed nilutamide as part of combined androgen blockade. The patient’s liver biopsy was consistent with a drug-induced hepatitis. The patient developed fulminant hepatic failure which appears attributable to the use of nilutamide as viral hepatitis infection, other infections, toxins, and autoimmune causes were excluded.

Case Report

A 76-year-old African American man with prostate cancer was transferred to our facility from a community hospital. The patient was initially diagnosed with prostate cancer 5 years ago, treated with a radical prostatectomy, and followed up by his urologist. The patient had been found to...


Nimesulide Hepatotoxicity Flutamide Fulminant Hepatic Failure Bicalutamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    McLeod DG (1997) Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 2(1):18–27PubMedGoogle Scholar
  2. 2.
    Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahl L, Bracken B, Brisset JM et al (1993) Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149:77–83PubMedGoogle Scholar
  3. 3.
    Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M et al (1991) Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 146(2):377–381PubMedGoogle Scholar
  4. 4.
    Boccardo F, Decensi AU, Guarner D, Martorana G, Fioretto L, Mini E et al (1991) Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer Detect Prev 15(6):501–503PubMedGoogle Scholar
  5. 5.
    Migliari R, Scarpa RM, Campus G, De Lisa A, Zucca I, D’Atri M et al (1991) Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer. Arch Ital Urol Nefrol Androl 63(1):147–153PubMedGoogle Scholar
  6. 6.
    Pescator P, Hammel P, Durand F, Berthau P, Bernuau J, Huc D et al (1993) Fatal fulminant hepatitis induced by nilutamide (Anondron). Gastroenterol Clin Biol 17(6–7):499–501Google Scholar
  7. 7.
    Marty F, Godart D, Doermann F, Merillon H (1996) Fatal fulminating hepatitis caused by nilutamide. A new case. Gastroenterol Clin Biol 20(8–9):710–711PubMedGoogle Scholar
  8. 8.
    Bracci U (1979) Antiandrogens in the treatment of prostatic cancer. Eur Urol 5(5):303–306PubMedGoogle Scholar
  9. 9.
    Bertagna C, de Gery A, Hucher M, Francois JP, Zanirato J (1994) Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 73(4):396–402PubMedCrossRefGoogle Scholar
  10. 10.
    Debruyne FM, Dijkman GA (1995) Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 28(3):177–188PubMedGoogle Scholar
  11. 11.
    Boelstirli UA, Ho HK, Zhou S, Leow KY (2006) Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 7(7):715–727. doi: 10.2174/138920006778520606 CrossRefGoogle Scholar
  12. 12.
    Fau D, Berson A, Eugene D, Fromenty B, Fisch C, Pessayre D (1992) Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J Pharmacol Exp Ther 263(1):69–77PubMedGoogle Scholar
  13. 13.
    Berson A, Schmets L, Fisch C, Fau D, Wolf C, Fromenty B et al (1994) Inhibition by Nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen. J Pharmacol Exp Ther 270(1):167–176PubMedGoogle Scholar
  14. 14.
    Lupron®. Product monograph (December 2007). TAP pharmaceuticals, Lake Forest, IL 60045, USAGoogle Scholar
  15. 15.
    Wysowski DK, Freiman JP, Tourtelot JB, Horton ML (1993) Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118(11):860–864PubMedGoogle Scholar
  16. 16.
    Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321(7):419–424PubMedGoogle Scholar
  17. 17.
    Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F et al (1993) Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 29A(8):1088–1093. doi: 10.1016/S0959-8049(05)80293-X PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Shehzad N. Merwat
    • 1
  • Wareef Kabbani
    • 2
  • Douglas G. Adler
    • 3
  1. 1.General Internal MedicineUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Department of PathologyUniversity of Texas Southwestern Medical CenterDallasUSA
  3. 3.Gastroenterology and HepatologyUniversity of Utah School of Medicine, Huntsman Cancer CenterSalt Lake CityUSA

Personalised recommendations